Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -50.4% | 0% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 546.3% | -1,368% | -926.3% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 412.3% | -1,397.1% | -822.7% |
| EPS Diluted | -0.47 | 0.14 | -0.97 | -0.78 |
| % Growth | -435.7% | 114.4% | -24.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |